Introduction
In the last few decades, the treatment outcome of children with ALL has improved thanks to more intensive chemotherapy, risk adapted strategies and improved supportive care. 1 This improvement has surpassed any that has ever been seen in adults with ALL. Although 80% of children aged 1-14 years are long-term survivors, less than 40% of adults are cured with current therapies. 2 Adolescents aged between 15 and 20 years of age are treated both by adult and paediatric teams, 3 following either adult or paediatric protocols. Their outcomes fall within the intermediate range, that is, worse than in children, although adolescents with ALL tolerate and respond to therapies that are used for children better than older patients do. Adolescent-specific Haematology/Oncology units are not frequent, except in the United Kingdom.
plays continues throughout adolescence, and a 10-year-old has half the chance of treatment failure as a 20-year-old does. 2, 7 Two questions need to be answered before stating how and where adolescents should be treated. What makes adolescents different? What is the best therapy for this group of patients?
What makes adolescents different?
According to the data that is available in the literature, two main factors are responsible for differences between adolescents and other age categories: disease biology and host factors.
The greater frequency of high-risk ALL subtypes in the adolescent population makes it extremely difficult to compare the therapeutic practices that are implemented in the treatment of adults with those that are used in children. The biological characteristics of adolescents with ALL display intermediate features that may be defined as being between those of the child and those of the adult populations. The frequency of ALL with T-cells in adolescents is similar to the 25% rate observed in adults, which is about two times higher than what is observed in younger children between the age of 1 and 14 years. 8 Few recurrent cytogenetic events are observed in this population: the frequency of hyperdiploidy involving more than 50 chromosomes is intermediate between the 25% rate observed in children and the 5% frequency displayed by adults. The frequency of t (9;22), t (4;11) and t (1;19) chromosomal translocations is also relatively low as compared with adults. 8 This lack of cytogenetic events in between the adult and childhood populations indicates the likely existence of unknown factors that would explain the worse prognosis of adolescents as compared with children. 3 Several studies have also reported differences in ALL cell sensitivity to corticosteroids and chemotherapy in vitro. 9, 10 As far as host factors are concerned, it is well known that organ function deteriorates with age. Other factors that have been observed in less young patients, and that are responsible for increased toxicity include differences in the metabolism of chemotherapeutic agents, depleted marrow reserve and increased extramedullary toxicity. All these issues lead to an increase in the frequency of lifethreatening infections, organ failure, treatment delays and reductions in chemotherapy dose.
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What is the best therapy for this group of patients?
The outcomes of adolescents who were treated with either paediatric or adult cooperative protocols have been compared in several studies. CR rates and EFS obtained by paediatric protocols are significantly higher and correlate with lower toxicity as compared with adult trials. Preliminary reports showed that adolescents may be at particularly high risk for treatment failure, despite aggressive chemotherapy-radiation therapy treatment. 12 More recent European studies have shown better outcomes in adolescents treated with paediatric protocols as compared with those treated with adult ones. [13] [14] [15] [16] An analysis carried out by the American Children's Cancer Group (CCG) showed similar results. 17 This difference is not only the result of a better CR rate but also of a lower relapse rate in the paediatric subgroup. 3 The higher survival rate of adolescents enrolled in paediatric trials cannot be accounted for by any significant differences in the patients' characteristics, and it can already be observed after the induction phase. This indicates that several factors may play a major role, including differences in protocol design, in drugs, in dose intensity, in the use of HSCT, as well as better compliance with treatment and better supportive care.
Historically, children treated at paediatric oncology centres are enrolled in complex clinical trials, which involve administering higher doses of major ALL treatment drugs that are delivered in a 2-3 year period, and that include an intensive phase before maintenance therapy. The benefits of this strategy, which was initially proposed by the BerlinFrankfurt-Munster study group, 18 have been demonstrated by the CCG study in children older than 10 years of age. 19 Moreover, patients aged 9-18 years receiving high doses of L-asparaginase during early treatment showed a significantly better outcome in a randomized study by the Paediatric Oncology Group. 20 It has recently been reported that adolescents are at increased risk of death during therapy for ALL. 21 Thus, as ALL is the most frequent type of paediatric cancer, paediatric oncologists are experts in the treatment and management of side effects. Paediatricians are extremely precise with regard to administering therapy owing to their convictions concerning the need to maintain the prescribed doses and schedules, whereas medical haematologists based in small centres cannot readily treat patients this way and may not have the facilities that are needed to provide supportive care. Furthermore, even most adult university centres do not have well-defined leukaemia-focused programmes. Disparities in the attitude towards treatment between paediatric and adult departments might also lead to the better outcome that is observed in paediatric institutions. 3 Moreover, paediatricians most often refer adolescents to paediatric academic medical centres where 490% of patients are o15-years old and where 490% of patients with ALL are enrolled in clinical trials. In contrast, internists more frequently refer adolescents to adult hospitals, mostly non-academic medical centres where 490% of the patients are 440 years of age and where most patients with ALL are not enrolled in clinical trials. 22, 23 This suggests that the lower participation rate in clinical trials for adolescents treated at adult institutions may partially explain the poorer survival, although the reasons for this remain unclear.
HSCT
The indications for HSCT in children with ALL in first or second CR are well defined by international protocols (Tables 1 and 2) . 24 Only very high-risk patients are eligible for HSCT in CR1, whereas more recently, owing to the poor general outcome, allogeneic or autologous HSCT are frequently offered in adult trials, even in standard-risk patients in CR1. 25 A retrospective survey on HSCT trends in children over the last three decades showed that age above 14 years significantly correlates with higher TRM, both in univariate and multivariate analysis Moreover, significantly lower TRM was observed among patients who were transplanted in centres performing more than 10 allogeneic transplants per year. Therefore, the effect of centre size and outcome confirms that a critical number of patients are needed to optimize outcome. 26 Bunin et al. recently demonstrated that patients above 15 years of age undergoing unrelated donor HSCT for ALL may expect a worse outcome than younger patients, with a TRM of 60% as compared with 38% for younger patients. 27 It has recently been shown that both advanced disease phase (Po0.0001) and age 410 years (Po0.002) are predictors for worse outcome after unrelated donor HSCT for ALL in children. Outcome is particularly favourable in younger patients in early phases of the disease. 28 Moreover, a tendency towards improved disease-free survival in younger patients as compared with older ones was shown by multivariate analysis in a study comparing outcomes of allogeneic HSCT in adult patients with ALL. 29 Thus, we can say that older age reduces disease-free survival in children given HSCT.
Graft-versus-host disease is an important factor influencing TRM and EFS. It has been reported that among patients with HLA identical sibling donors, given GVHD prophylaxis made up of a combination of MTX and CsA, older recipient age (Po0.0001) is the single most important risk factor for chronic GVHD. 30 More recently, a paper published by the AIEOP-HSCT group showed that recipient age above 15 years significantly correlates with a higher risk of chronic GVHD occurrence, but that it does not impact TRM or EFS. 31 
Psychological issues
A further issue that must be taken into consideration concerns the various psychological factors related to adolescence. Adolescence is a difficult time, especially for those with malignancies, and as of 1959 it has been recommended that teenagers be cared for in an environment designated for them, as they are more suited to an environment of peers and would thus benefit from this. 32 Adolescents who are treated in a centre that is specifically geared and exclusive to them are significantly more satisfied with several aspects of their care than those treated in either adult or paediatric centres. 4 Access to education, recreational and relaxation facilities, study space, peer companionship, hospital food and noise levels within the ward should be taken into consideration before admitting an adolescent to a ward. Paediatricians or haematologists should try to understand how important it is for adolescents to be kept up to date about examinations and choices that will affect the rest of their lives. The parents of children with ALL usually ensure compliance of their children undergoing prolonged chemotherapy. However, adolescents also often need intensive psychosocial support, especially when coping with the acute and chronic toxicities of treatment, 11, 22 and thus compliance may be problematic. It is frequently thought that for adolescents, his or her physician is sufficient for optimal care and outcomes, whereas paediatricians believe that even the best motivated patient can have his treatments and outcomes enhanced by the presence of parents, family members and a supportive team of professionals. They may actually contribute to optimal adherence to protocol, emotional support and better outcomes.
Improving psychosocial support during therapy, preventing treatment-related sequelae, increasing the continuity of health care as adolescents transition into adulthood and increasing knowledge and practice of healthy dietary and physical exercise lifestyle habits represent further challenges for teams involved in the treatment of adolescents.
Future direction
The EBMT PDsWP has been attempting to increase the upper age limits of paediatric age to 18 years. However, modifying the review systems of clinical trials as well as national regulations is not easy. Thus, diseases such as ALL, whose biology extends across a broad age spectrum, are usually treated as more than one single disease: childhood ALL (patients o14, or o16, or o18 years old) and adult ALL (patients 418 years old).
Cooperation between paediatric and adult haematologists will improve the opportunity to accrue as many patients as possible and will promote progress in the research on adolescents. Cooperation of this sort could lead to intergroup trials with no age limits, which would minimize competing protocols.
Conclusions
Adolescents with ALL have suffered because little progress has been made over the decades with regard to disease outcome. This is because of the lack of acknowledgement of the existing need, no access to or availability of Table 1 Indications for HLA-matched related or unrelated donor SCT in CR1, according to BFM criteria No response at induction treatment Ph-positive ALL T-cell ALL and prednisone poor response High load of minimal residual disease as defined in National Protocols Table 2 Indications for matched related donor SCT in second CR (modified BFM criteria) Isolated BM relapse and duration of CR1 o30 months (o48 for AIEOP) Any duration of CR1 and high MRD load as defined in National Protocols (not applicable for some countries) T-cell ALL (AIEOP) Abbreviations: AIEOP ¼ Italian Association for Paediatric Haematology and Oncology; MRD ¼ minimal residual disease.
prospective clinical trials, the lack of biologic samples for basic and translational research and the lack of psychosocial support for patients, all of which have been hampered by the fragmentation of care between paediatric and adult haematologists. The international community needs to acknowledge this poorly served population and work together to bring about positive change. This will involve a concerted effort to eliminate barriers to clinical trial enrollment and to educate the medical community as well as the general public concerning the importance of developing clinical trials. The aim of these efforts is to obtain biologic samples, to prospectively study treatments for these diseases with emphasis on new agents and to evaluate the toxicity and links to the biology of this age group.
In conclusion, redefining age limits on the basis of riskbased strategies and multi-centre cooperation should be taken into consideration to improve the outcome of this age category.
Adolescents should be referred to research treatment teams that have experience in the management of paediatric ALL and they should be enrolled in international cooperative studies. Molecular, genetic and proteomic evaluation may cast further light on the causes of the rather striking decrease in survival that is seen as the patient progresses from childhood to adolescence.
